The following table provides an overview of the latest patents of Nektar Therapeutics that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3134123Feb 17, 2021Il-2Rbeta-Selective Agonists In Combination With An Anti-Ctla-4 Antibody Or An An Anti-Pd-1 Antibody2
EP2453962Mar 14, 2018Negatively Biased Sealed Nebulizers Systems And Methods1
EP3094331Dec 27, 2017Combination-Based Treatment Method1